Research and development is the heart and soul of Bristol-Myers Squibb’s BioPharma strategy, whether we’re working alone or in a partnership. With about 50 compounds in development, a network of research facilities around the globe, and an annual R&D budget of more than $3 billion, Bristol-Myers Squibb’s organization ranks as one of the premier R&D organizations in the industry.

We believe that by combining great science with rigorous development focused on unmet medical needs, we can bring innovative medicines to patients.

We seek to engage with top tier organizations to accomplish this goal. By pooling the talents of our science and business teams, Bristol-Myers Squibb has engaged in numerous collaborations with a range of companies and research institutions. These collaborations fit in with our strategy of focusing on 6 specific disease areas, concentrating on biologics and continuing to invest in new and in-line drivers of growth as well as priority R&D programs that support our pipeline.